Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists


Ontology type: sgo:Patent     


Patent Info

DATE

2022-03-15T00:00

AUTHORS

RESCOURIO GWENAELLA , GONZALEZ BUENROSTRO ANA , BROWN SEAN P , LIZARZABURU MIKE , MEDINA JULIO , JABRI SALMAN YOJIRO , SUN DAQING , SIMONOVICH SCOTT PRESTON , YAN XUELEI , LI YIHONG , REW YOSUP

ABSTRACT

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. More... »

Related SciGraph Publications

  • 2008-12. BCL-2 family antagonists for cancer therapy in NATURE REVIEWS DRUG DISCOVERY
  • 2008-12-16. Mcl-1 is a potential therapeutic target in multiple types of cancer in CELLULAR AND MOLECULAR LIFE SCIENCES
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/34", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/31", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3101", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "name": "RESCOURIO GWENAELLA", 
            "type": "Person"
          }, 
          {
            "name": "GONZALEZ BUENROSTRO ANA", 
            "type": "Person"
          }, 
          {
            "name": "BROWN SEAN P", 
            "type": "Person"
          }, 
          {
            "name": "LIZARZABURU MIKE", 
            "type": "Person"
          }, 
          {
            "name": "MEDINA JULIO", 
            "type": "Person"
          }, 
          {
            "name": "JABRI SALMAN YOJIRO", 
            "type": "Person"
          }, 
          {
            "name": "SUN DAQING", 
            "type": "Person"
          }, 
          {
            "name": "SIMONOVICH SCOTT PRESTON", 
            "type": "Person"
          }, 
          {
            "name": "YAN XUELEI", 
            "type": "Person"
          }, 
          {
            "name": "LI YIHONG", 
            "type": "Person"
          }, 
          {
            "name": "REW YOSUP", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nrd2658", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030857223", 
              "https://doi.org/10.1038/nrd2658"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-008-8637-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023498818", 
              "https://doi.org/10.1007/s00018-008-8637-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-03-15T00:00", 
        "description": "

    Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

    ", "endDate": "2039-03-04", "id": "sg:patent.US-11274105-B2", "name": "Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.417886.4", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-11274105-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-11-24T21:23", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/patent/patent_45.jsonl", "type": "Patent" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-11274105-B2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-11274105-B2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-11274105-B2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-11274105-B2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    77 TRIPLES      15 PREDICATES      19 URIs      9 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:patent.US-11274105-B2 schema:about anzsrc-for:31
    2 anzsrc-for:3101
    3 anzsrc-for:34
    4 schema:author Ne847002a9e084ff990db59207fb0b9ab
    5 schema:citation sg:pub.10.1007/s00018-008-8637-6
    6 sg:pub.10.1038/nrd2658
    7 schema:datePublished 2022-03-15T00:00
    8 schema:description <p>Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.</p>
    9 schema:endDate 2039-03-04
    10 schema:name Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists
    11 schema:recipient grid-institutes:grid.417886.4
    12 schema:sameAs https://app.dimensions.ai/details/patent/US-11274105-B2
    13 schema:sdDatePublished 2022-11-24T21:23
    14 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    15 schema:sdPublisher N1c6b73bb01494ca79858aa76853158d1
    16 sgo:license sg:explorer/license/
    17 sgo:sdDataset patents
    18 rdf:type sgo:Patent
    19 N001b68588f8449e4ab620413c04f8104 rdf:first N7de3e9fffb6f45309d3c5d69142ecd4e
    20 rdf:rest Nd45d055d55924c1b9e28f6f4d33d03cd
    21 N0f593b79eb1444989acc3868262bebbc schema:name JABRI SALMAN YOJIRO
    22 rdf:type schema:Person
    23 N1c6b73bb01494ca79858aa76853158d1 schema:name Springer Nature - SN SciGraph project
    24 rdf:type schema:Organization
    25 N276e41c7fcc34e51bd3207f2330a6445 rdf:first N96941af3396e4415b81414ccee5749ad
    26 rdf:rest N001b68588f8449e4ab620413c04f8104
    27 N331049de33064aca93761260beaafb2b schema:name REW YOSUP
    28 rdf:type schema:Person
    29 N3e66a33f34104dd4932acb7e27ae493f rdf:first N331049de33064aca93761260beaafb2b
    30 rdf:rest rdf:nil
    31 N446803da49f0411c8c0350e83020d898 schema:name MEDINA JULIO
    32 rdf:type schema:Person
    33 N4495dd89b98c45898e739bee3c4d07f1 rdf:first Nf853be94cc0e45b3b548a5ddfde6d6c6
    34 rdf:rest Nf0b87b984fa840d59ce7b9bac06fe720
    35 N583fc43bef3e418c92c581ea909bd854 rdf:first N446803da49f0411c8c0350e83020d898
    36 rdf:rest Nb10fd0ff5c0849ecb9bc068466dc028c
    37 N7a327a80bb2d4cfd946eeaadf8d042c1 schema:name BROWN SEAN P
    38 rdf:type schema:Person
    39 N7de3e9fffb6f45309d3c5d69142ecd4e schema:name SIMONOVICH SCOTT PRESTON
    40 rdf:type schema:Person
    41 N8814125667404f109234e1a34be04167 schema:name RESCOURIO GWENAELLA
    42 rdf:type schema:Person
    43 N8f007bdecbc045aaa2a9a89c0bb480f9 schema:name LIZARZABURU MIKE
    44 rdf:type schema:Person
    45 N96941af3396e4415b81414ccee5749ad schema:name SUN DAQING
    46 rdf:type schema:Person
    47 Nb10fd0ff5c0849ecb9bc068466dc028c rdf:first N0f593b79eb1444989acc3868262bebbc
    48 rdf:rest N276e41c7fcc34e51bd3207f2330a6445
    49 Nb1ef5f6f503b4dbd8f24cef3cb225f0c rdf:first Nba116189ba854ad6a9f9df313a0db725
    50 rdf:rest N3e66a33f34104dd4932acb7e27ae493f
    51 Nb78accb56e244fa28f00aba2795ed357 rdf:first N8f007bdecbc045aaa2a9a89c0bb480f9
    52 rdf:rest N583fc43bef3e418c92c581ea909bd854
    53 Nb8d4f40f9e414174ba7f24e2c91da3dc schema:name YAN XUELEI
    54 rdf:type schema:Person
    55 Nba116189ba854ad6a9f9df313a0db725 schema:name LI YIHONG
    56 rdf:type schema:Person
    57 Nd45d055d55924c1b9e28f6f4d33d03cd rdf:first Nb8d4f40f9e414174ba7f24e2c91da3dc
    58 rdf:rest Nb1ef5f6f503b4dbd8f24cef3cb225f0c
    59 Ne847002a9e084ff990db59207fb0b9ab rdf:first N8814125667404f109234e1a34be04167
    60 rdf:rest N4495dd89b98c45898e739bee3c4d07f1
    61 Nf0b87b984fa840d59ce7b9bac06fe720 rdf:first N7a327a80bb2d4cfd946eeaadf8d042c1
    62 rdf:rest Nb78accb56e244fa28f00aba2795ed357
    63 Nf853be94cc0e45b3b548a5ddfde6d6c6 schema:name GONZALEZ BUENROSTRO ANA
    64 rdf:type schema:Person
    65 anzsrc-for:31 schema:inDefinedTermSet anzsrc-for:
    66 rdf:type schema:DefinedTerm
    67 anzsrc-for:3101 schema:inDefinedTermSet anzsrc-for:
    68 rdf:type schema:DefinedTerm
    69 anzsrc-for:34 schema:inDefinedTermSet anzsrc-for:
    70 rdf:type schema:DefinedTerm
    71 sg:pub.10.1007/s00018-008-8637-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023498818
    72 https://doi.org/10.1007/s00018-008-8637-6
    73 rdf:type schema:CreativeWork
    74 sg:pub.10.1038/nrd2658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030857223
    75 https://doi.org/10.1038/nrd2658
    76 rdf:type schema:CreativeWork
    77 grid-institutes:grid.417886.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...